HemoShear Therapeutics is a drug discovery company structured primarily around discovery of new treatments for patients with rare metabolic disorders. With several partnerships arrangement with biopharma companies to accelerate their drug discovery and development programs in liver diseases, gout, cancer and other conditions, the effort is to offer a new vision for how advanced biological systems can yield new insights that improve health and quality of life for patients in need and on development of drugs for children who are born with metabolic defects, unable to sustain basic biochemical processes necessary for life. The firm's proprietary Drug Discovery Platorm supports recapitulation of diseases using tissue from livers of children born with genetic defects, enabling Hemoshear's personnel to interrogate the disrupted biochemical processes, explore drug intervention strategies, and select drug candidates that are judge likely to have high probabilities of clinical success. This very specialized capacity and proprietary human disease models gives the firm capabilities to recreate and interpret complex human biology - to understand human hepatic, tumor, or vascular disease biology then to translate those findings into discovery of safe and effective drug treatments. HemoShearÂ’s current drug discovery programs are focused on nonalcoholic steatohepatitis (NASH) and propionic and methylmalonic acidemias, rare genetic metabolic disorders. In 2018 it was announced that SmartZyme BioPharma Inc. had spun off its protein engineering platform into a new company named Carnot BioSciences LLC to collaborate with HemoShear Therapeutics LLC on the development of protein-based therapies for rare metabolic diseases. In 2019 HemoShear Therapeutics, LLC. announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).
